Abstract Number: 2636 • ACR Convergence 2025
Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
Background/Purpose: People with axial spondyloarthritis (axSpA), typically present with persistent back pain and experience up to a 10-year diagnostic delay that may lead to irreversible…Abstract Number: 0008 • ACR Convergence 2025
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…Abstract Number: 0296 • ACR Convergence 2025
Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies
Background/Purpose: Autoimmune inflammatory myopathies (IMs) comprise a diverse group of diseases that primarily affect the muscles and often involve the lungs, skin, and joints. Among…Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…Abstract Number: 0953 • ACR Convergence 2025
NMDAR Autoantibody-Induced Neuronal Damage in the Amygdala Mediates Mood and Anxiety Disorders in a Model of Neuropsychiatric Lupus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease characterized by aberrant production of autoantibodies and chronic inflammation. Up to 80% of individuals with…Abstract Number: 1488 • ACR Convergence 2025
Limited Concordance Between anti-dsDNA Assays and Association with Lupus Nephritis
Background/Purpose: Anti-dsDNA antibodies are a key diagnostic marker of systemic lupus erythematosus (SLE), often associated with active disease. Its presence is detected using various commercial…Abstract Number: 2027 • ACR Convergence 2025
Development of a multi-disease panel for autoimmune diseases
Background/Purpose: Autoantibodies serve as important biomarkers for diagnosing autoimmune diseases. However, current clinical assays for their detection often face challenges, such as uncertainty about the…Abstract Number: 2414 • ACR Convergence 2025
Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
Background/Purpose: Up to a third of those with suspected SLE progress to definite SLE; however, reliable predictive markers for disease progression remain unknown. Previously, we…Abstract Number: 2652 • ACR Convergence 2025
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…Abstract Number: L11 • ACR Convergence 2024
Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…Abstract Number: 0308 • ACR Convergence 2024
Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality. The prevalence and characteristics of new…Abstract Number: 0673 • ACR Convergence 2024
BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients
Background/Purpose: Medication free complete remission (CR) has been elusive in SLE. An open label investigator-initiated trial (IIT) infused SLE/LN patients with a novel cCAR targeting…Abstract Number: 1161 • ACR Convergence 2024
Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…Abstract Number: 1589 • ACR Convergence 2024
Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis
Background/Purpose: Hallmark autoantibody reactivities predict different patterns of skin involvement and risk of internal organ involvement. We have asked whether whole skin gene expression may…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 37
- Next Page »
